Abstract
Background This study aims to develop a model for simultaneously assessing genetic and epigenetic contributions to plasma lipid levels.
Methods The predictive model was developed using two cardiovascular risk groups, i.e., individuals with high low-density lipoprotein cholesterol (LDL-C) levels (≥160 mg/dl, N = 296) and coronary artery disease (CAD) (N = 315), in contrast to reference (max N = 3,801) and non-CAD individuals (N = 164). For genetic predisposition, rare pathological variants in five target genes related to familial hypercholesterolemia (FH) were screened, while common variants were characterized to calculate a polygenic risk score (PRS). The methylation risk score (MRS) was also calculated for epigenetic profiles based on DNA methylation levels at 13 CpG sites. A relationship between these variables and lipid levels was analyzed in regression and quantile models.
Results A total of 17 rare FH-related gene variants were identified in patients with high LDL-C or CAD, significantly more prevalent than in the general Japanese population (2.8% vs. 0.2%, P <1×10−15). For the rare variants plus PRS, the predictability of individual LDL-C increased (correlation coefficient between predicted and measured values, r = 0.261, P = 1.7×10−11) compared to PRS alone (r = 0.151, P = 1.2×10−4). PRS and MRS had the most significant impact on high-density lipoprotein cholesterol and triglycerides, respectively. The two risk scores had additive effects on these traits.
Conclusions Our results provide proof-of-concept that assessing the relative contribution of genetic predisposition and DNA methylation levels (reflecting past environmental exposures) may help individuals refine their dyslipidemia treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a grant (19A2004) from NCGM and AMED under Grant Number JP22ek0210165 and JSPS KAKENHI Grants (JP20K10514, JP21H03206, JP22H03350).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional ethics review board at the National Center for Global Health and Medicine (NCGM) approved this study, and participants gave their written informed consent. The procedures followed the ethical standards of the institutional committee on human experimentation at NCGM.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
All data produced in the present study are available upon reasonable request to the authors.
